Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citation
Cited by
Items 701–800 of 814
Wang, H., Zhao, R., Liu, M., Jiang, T., Sun, D., Chi, L., Huang, Y., Lu, Z., YUN, Y., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1812063 · Cited by 1
Gustine, J. N., Attar, N., Puliafito, B. R., Cirstea, D. D., Branagan, A. R., Yee, A. J., & Raje, N. S. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01510-1
Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaPreprint
Talbot, A., Li, K., Lee, J. H. J., Lang, S., Liu, C., Kalter, N., Li, Z., Mortazavi, Y., Almudhfar, N., Muldoon, J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.20.719660 · Cited by 1
Self-citationRodríguez‐Otero, P., Pérez‐Larraya, J. G., Lin, Y., Dietrich, J., van de Donk, N. W. C. J., Mason, X. L., Dhakal, B., Jakubowiak, A. J., Lendvai, N. K., Li, H., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.013 · Cited by 3
Self-citationTargeting the immunological synapse in multiple myeloma
Sumei, L., & Bahmani, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-05125-7
“To keep the clinical hierarchy explicit, the strongest current human evidence sits with approved CAR-T and bispecific programs, including ide-cel (median PFS 8.8 months in KarMMa) [93], randomized phase 3 evaluation of cilta-cel [119], and teclistamab supported by MajesTEC-1 and FDA review [120].”
InfluentialMaking the case for ruxolitinib in CAR T-cell enterocolitis
Hamilton, M. P., & Kebriaei, P. (2026) · Blood · doi:10.1182/blood.2025032940
Li, H., Xia, Q., Yu, M., Lv, Y., Xiao, J., Guo, X., Dong, K., Zhou, Y., Zhong, L., Wang, T., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3227-0
“…(orva-cel), CT053, and P-BCMA-101 continue to explore variations in scFv design and co-stimulatory domains to optimize efficacy and safety (Asherie et al., 2023; Cowan et al., 2023; Frigault et al., 2023; Lin et al., 2023; Manier et al., 2022; Rodriguez-Otero et al., 2023; San-Miguel et al., 2023).”
Oswald, L. B., Li, X., Gudenkauf, L. M., Avila, G. D., Scheiber-Camoretti, D., Small, B. J., Gonzalez, B. D., Hoogland, A. I., Nguyen, O., Rodriguez, Y., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02899-w
“Accordingly, ide-cel and cilta-cel were FDA-approved as fi fth-line therapies for RRMM in March 2021 [6] and February 2022 [7], respectively, and have since been approved as earlier lines of therapy [8, 9].”
Pisaturo, M., Grimaldi, P., Palma, M. D., Onorato, L., D’Ambrosio, A., Frigeri, F., & Coppola, N. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116790
El‐Sehrawy, A. A. M. A., Oriquat, G., Saidov, S., Ruzikulov, U., Shakhmurova, G., Jbl, B. J., Singhal, D., & Shefali (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121066 · Cited by 1
Kuipers, M. T., Migchelbrink, J., Kramer, A. M., Kouwenhoven, M. C. M., Zweegman, S., Groen, K., & van de Donk, N. W. C. J. (2026) · BioDrugs · doi:10.1007/s40259-026-00784-y
“%) in CARTI-TUDE-1, but at a lower rate in CARTITUDE-4 in patients who received 1–3 prior lines (all grade ICANS: 4.5% [no grade 3 events]) [4, 7].”
InfluentialSelf-citationMartínez, D., Sopeña, C., Moreno, M. J., Sánchez, M., Gascón, A., Lorente, P., Montagud, M., Martí, J. P., Rios, S. J., Arnao, M., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.002
Disparity in access to multiple myeloma CAR-T: a geospatial analysis of distance to CAR-T centers
Daunov, M., Gorham, R., Lytvynova, O., Chaekal, O.-K., O'Brien, T., van Besien, K., Dong, W., Koroukian, S. M., & Ignatz-Hoover, J. J. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100064
Tan, J. Y., Vignarajah, A., Ng, L. S., Nurliyanah, A., O'Leary, D., & Hilal, T. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2673104
“Patients with relapsed or refractory MM receiving cilta-cel therapy had a higher CrS compared to patients receiving BsAbs. in clinical trial and real-world study, CrS rates of cilta-cel therapy group range from 76–85% [4,5].”
Hansen, D., Puglianini, O. A. C., Grajales-Cruz, A. F., Nagar, S. P., Ghosh, S., Alegria, V., Braganca, K. C. D., Lengil, T., Sharma, M., Pai, H., et al. (2026) · Clinical Epidemiology · doi:10.2147/clep.s615866 · Cited by 1
“5 The CARTITUDE-1 trial demonstrated deep and durable responses in heavily pretreated patients, 6–8 and CARTITUDE-4 showed improved progression-free and overall survival in earlier lines, 9,10 supporting expanded approval in 2024 among lenalidomide-refractory patients after ≥1 prior LOT.”
Zhou, C.-Q., Zhou, S.-Q., & Ke, Q.-H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1811170
Liu, S. X., Wu, J., Liu, J., Wu, K., Huang, Y. Q., Geng, S., Wang, Y., Weng, J., Du, X., & Lai, P. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s605729
“5,6 In the pivotal CARTITUDE-4 trial, ciltacabtagene autoleucel significantly prolonged progression-free survival compared to standard of care.”
Clinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04229-8
“%) reported in the standard-of-care group [57].”
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Self-citationRedefining Early Relapse in Multiple Myeloma — Time to Change the Rules
Mateos, M. (2026) · New England Journal of Medicine · doi:10.1056/nejme2605404
Self-citationLi, J., Dowling, M. R., Wronski, M., Kazzi, C., Fiorenza, S., Cherk, M. H., Wong, S. M., Inam, S., Barber, T. W., Monif, M., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.027
Self-citationBerning, P., Maulhardt, M., Boyadzhiev, H., Albici, A., Janjetovic, S., Saidy, A. O., Schultze-Florey, C. R., Call, S., Stölzel, F., Brioli, A., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01531-w
Hansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
Self-citationJimenez-Mira, C., Tovar, N., Martínez‐Cibrián, N., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70586
“11,12 In addition, academic products like cesnicabtagene autoleucel (cesni-cel; ARI0002h) have also shown relevant clinical activity and represent a valid alternative to overcome accessibility issues and unmet medical needs (PCL, CNS-MM and other rare complications) not previously explored in…”
Self-citationIbarra-Garcia, V., Calleja-Cervantes, M. E., Rochira, F., Azagra-Barber, I., Martín‐Úriz, P. S., Aguirre-Ruiz, P., Rodríguez-Diaz, S., Martínez-Turrillas, R., Iglesias, E., Ibáñez-Sala, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729637
Self-citationPivotal trial design considerations for new and next generation cell and gene therapies
Anderson, P., Xu, Z., Degtyarev, E., Ananthakrishnan, R., Ballarini, N. M., He, A., Zhang, W., & Li, D. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2670523
Dachy, G., Mooyaart, J., Gabellier, L., Yakoub‐Agha, I., Daskalakis, M., Potter, V. T., Dreger, P., Huynh, A., Scheid, C., Collin, M., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02925-x
“During the last decade, therapy with chimeric antigen receptor T-cells (CAR T-cells) has revolutionized the fi eld of cellular therapies [1] for B cell acute lymphoblastic leukemias [2], B cell lymphomas [3, 4], and multiple myeloma [5, 6].”
Irfan, S., Jamil, M. A., & Abid, M. B. (2026) · British Journal of Haematology · doi:10.1111/bjh.70607
Golec, S., Fu, W., Moshier, E., Peleg, A., Pileggi, B., Rossi, A., & Sahni, G. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag097
“10,11 This patient population is at high baseline risk of cardiovascular (CV) disease, both because patients present at an advanced age with pre-existing CV risk factors and because prior treatment with anthracyclines, proteasome inhibitors, stem cell trans-plants, and mediastinal radiation therapy…”
CRISPR application in hematological disorders: from bench to bedside
Ladisa, F., Morelli, E., Soncini, D., Garibotto, M., Munshi, N. C., Fulciniti, M., & Cea, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017417 · Cited by 1
Orofino, G., Sánchez‐Ortega, I., Mota, J. S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104014
Camargo, C., Corona-Arias, C. A., Sandoval, Y. C. C., Ballesteros, W. G. G., Agudelo, D. S. J., & Romero, G. I. T. (2026) · Journal of Applied Hematology · doi:10.4103/joah.joah_23_26
Suvannasankha, A., Li, M., Omofuma, O. O., Hampp, C., Phelan, M., Breskin, A., Shao, P., Roccia, T., Mukherjee, N., Shrestha, A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4068
“To date, only 2 clinical trials have directly compared the risk of SPM following CAR T therapy versus other systemic anticancer therapy (SACT) in patients with multiple myeloma (13, 14), but the sample sizes were relatively small.”
InfluentialCazaubiel, T., Touzeau, C., Vincent, L., Belhadj, K., Karlin, L., Manier, S., Perrot, A., Vekemans, M. C., Moyer, P., Moreau, P., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.005
Self-citationWerner, J., Gödel, P., Galldiks, N., Krone, C., Schroeter, M., Holtick, U., Flümann, R., Wunderlich, G., Hallek, M. J., Fink, G. R., et al. (2026) · HemaSphere · doi:10.1002/hem3.70404
Maura, F., Firestone, R., & Usmani, S. Z. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01199-2
Chatterjee, P., Kundu, A., Giri, S., & Basu, A. (2026) · Cureus · doi:10.7759/cureus.111117
“Although the prognosis of pPCL remains poor overall, advances in targeted therapy, transplantation strategies, and minimal residual disease assessment are gradually improving survival outcomes [18,20].”
de Boissieu, P., Lengliné, É., & Chevret, S. (2026) · British Journal of Haematology · doi:10.1111/bjh.70629
MRD in multiple myeloma: Moving from “minimal” to “measurable”
Cassano, R. C., Banerjee, R. K., Afrough, A., Portuguese, A. J., Thakur, R., Cicero, K. I., Kwok, M., Foster, L. H., Buda, G., Meletath, S. K., et al. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101413
Cashman, H. P., & Turtle, C. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819591 · Cited by 2
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Self-citationIMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Rajeeve, S., Nagar, S. P., Ghosh, S., Alegria, V., Hayne, J., Emond, B., Maitland, J., Qureshi, Z. P., & Anderson, L. D. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00455-6
“This may be more easily achieved in earlier-line patients with relatively lower treat-ment refractoriness than in later-line patients, which supports efforts to maximize treatment benefit by using effective therapies early in the disease course [17].”
InfluentialJanakiram, M., Ghosh, S., Alegria, V., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0052
“In clinical trials, cilta-cel was primarily administered in the inpatient (IP) setting to allow for close monitoring of acute toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [1 , 2] .”
Neurological complications of current and emerging CAR-T cell therapies
Hauswirth, A. G., & Dietrich, J. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00951 · Cited by 1
“…in the initial study of ciltacabtagene autoleucel (CARTITUDE-1) but subsequently in only one patient out of 208 in the phase 3 trial after implementation of a prevention program that prioritized reducing tumor burden prior to CAR-T and aggressive treatment of ICANS and CRS (CARTITUDE-4) [30,35].”
Kidney Transplantation Post–Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma
Khan, Z., Dadhania, D. M., Brailovski, E., Landau, H. J., & Shaikh, A. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.012 · Cited by 1
Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients
Bergantim, R., Roque, A. I., Jorge, A., Freitas, J. G., Miranda, M. T., Nunes, M., Ionita, A., Bernardo, P. V., Vieira, J., Aguiar, E. V., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1847793 · Cited by 1
“…(ide-cel) and ciltacabtagene autoleucel (cilta-cel), have been approved for patients who have received ≥ 3 prior lines of therapy, with cilta-cel additionally approved for lenalidomide-refractory patients following one to three prior lines of therapy based on the phase 3 CARTITUDE-4 trial (61, 62).”
CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment
de Jong, D., McGale, J., Robinson, T. J., Liao, M. J., Das, J. P., Major, A., Capaccione, K. M., Ladbury, C., Mansilla‐Soto, J., Ma, H., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266605
“Later results demonstrated that a single infusion of a BCMA-targeted agent resulted in a lower risk of disease progression or death as well as prolonged OS when compared with the standard of care in patients with refractory multiple myeloma ( 19 , 20 ).”
Straßl, I., Nikoloudis, A., Rüsing, L. Z., Melchardt, T., Leisch, M., Schulz, E., Heine, A., Neumeister, P., Steiner, N., Wolf, D., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.06.048
Paiva, B., Manrique, I., Thompson, E. G., Campbell, T., Guerrero, C., Martin, N., Anderson, L. D., Berdeja, J. G., Lonial, S., Raje, N. S., et al. (2026) · HemaSphere · doi:10.1002/hem3.70423
Self-citationUnkenholz, C., Ortega-Vida, E., Monge, J., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100267
“Its success with overall response rates >70% and durability that exceeds those of many other therapies 8-10 , as well as its limitations with severe hypogammaglobulinemia being commonplace, makes it an ideal therapy to study possible prognostic markers.”
Expedited regulatory approval pathways for novel oncology drugs
Shukla, V. K., Chauhan, A., Malakar, K., & Rana, M. (2026) · Medical Oncology · doi:10.1007/s12032-026-03313-7
Miebach, L., Schwarzer, A., Grunwald, U., Alkhayer, A., Grothe, M., Neumann, T., Krüger, W., & Krönke, J. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100070
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma
Worth, H. A., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70519
“The therapeutic options for patients with RRMM and one to three ide - cel 19,20 and cilta - cel 21,22 have proven superiority over conventional regimens.”
Self-citationRodrigues, M. S., Silva, L. A., & Silva, C. E. D. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10253153/v1
Elranatamab: A novel B-cell maturation T-cell engager
Hossain, S., & Bianchi, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2694852
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
Samuel, M., Flores, M. S., Lowy, J. A., Rogers, M. F., Avigan, Z. M., Rattu, M. A., & Richter, J. R. (2026) · Future Oncology · doi:10.1080/14796694.2026.2700028 · Cited by 1
Mukherjee, A. M. (2026) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000150
CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences
Bach, D., & Nguyen, T. U. O. N. G. (2026) · Human Gene Therapy · doi:10.1177/10430342261467645
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Sra, M. S., & Kumar, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2703858
“…which randomized 419 patients with 1–3 prior lines of lenalidomide-refractory multiple myeloma to cilta-cel versus standard-of-care triplets, demonstrated a 74% relative reduction in risk of progression or death, with 30-month PFS of 59.4% and overall survival of 76.4% in the cilta-cel arm [22,23].”
InfluentialCarlson, S. G., Puliafito, B. R., Kawai, K., Senaratne, T. N., Lee, T. D., Lin, T., Timmerman, J. M., & Larson, S. M. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04249-4 · Cited by 2
Lymphocyte collection for cellular therapy
Filho, S. L. A. P., Barbosa, S. T., de Castro, N. C. M., et al. (2026) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2025v7n1e330
Wang, X., Hu, P., Steimle, B. L., Wagner, M., Langan, P. S., Luo, K., Nurmukhambetova, S. T., Liang, G., Tran, N., Xiong, W., et al. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100078 · Cited by 1
When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era
Afrough, A., Dillard, C. M., Alsup, A., Lee, J. H., Hadidi, S. A., Sannareddy, A., Abraham, P. R., Turer, L., Dima, D., Khan, A. M., et al. (2026) · Cancers · doi:10.3390/cancers18152415
“A similar pattern was observed in the phase III CARTITUDE-4 trial, which investigated cilta-cel in patients who had received one to three prior lines of therapy and were refractory to lenalidomide [97].”
Self-citationDe-escalation trials in multiple myeloma: past, present and future
Mian, H. S., Costa, L. J., Mohty, M., Garfall, A. L., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01186-3
“Building on this evidence, the phase III CARTITUDE-4 trial 47 demonstrated that a single CAR T cell infusion without maintenance can lead to excellent and durable outcomes in patients with lenalidomide-refractory disease, with a 12-month PFS of 76% 47 .”
Self-citationJurgens, E. M., Mitra, S., Herrera, K., Nemirovsky, D., Bready, B., Derkach, A., Hosszu, K., McAvoy, D. P., Firestone, R., Rajeeve, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed0039 · Cited by 2
Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Shivarov, V. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00021-7
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
Tan, C. R., & Mailankody, S. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01191-6
Akrawi, D., Datta, S., Hatipoğlu, S., Wechalekar, A. D., Ghose, A., Alkhateeb, A., Walker, J. M., & Ghosh, A. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02397-x
“…disease, treatment increasingly shifts to T-cell–redirecting therapies, including B-cell maturation antigen (BCMA)- directed CAR-T therapies such as ide-cel and cilta-cel, and bispecific antibodies targeting BCMA or GPRC5D, such as teclistamab, elranatamab, linvoseltamab, and talquetamab [ 26–29].”
Harnessing the Power of CAR-T Cells in Hematologic and Solid Tumors
Habibi, S., Jalise, S. Z., Afkhami, H., Motaghi, R., & Sheykhhasan, M. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_7
Podar, K. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01121-3
CAR-T-Zelltherapien in der Behandlung von B-Zell-Neoplasien
Roerden, M., & Bethge, W. A. (2026) · TumorDiagnostik & Therapie · doi:10.1055/a-2823-2802
Besemer, B., & Schenk, A. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2807-6023
Zolotov, E., Mody, R., Doucette, K., Chappell, A., Accolatse-Mati, C., Parmar, H. V., Palma-Grisi, J. D., Biran, N., Phull, P. M., Franz, J., et al. (2026) · Current Oncology · doi:10.3390/curroncol33080475
“However, patients with ESRD requiring HD were systematically excluded from these studies: KarMMa and KarMMa-3 mandated creatinine clearance (CrCl) ≥ 45 mL/min, and CARTITUDE-4 required CrCl ≥ 40 mL/min [7–10].”
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 1
Li, S., Huang, J., Fang, R., Zhang, M., Jin, Y., Zhu, Y., & Ma, C. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152541
Barilà, G., Grassi, A., Ruocco, V., Liberatore, C., Olivari, E., Tinelli, M., Fazio, F., Morè, S., Favero, E., Cartia, C. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70751
Venglár, O., Radova, E., Warmuzová, M., Bilek, D., Kudelkova, M., Jasinkova, K., Muroňová, L., Broskevičová, L., Kapustová, V., Vrána, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70455
“4,18 In contrast, analysis of 35 PB samples from the same cohort indicated that mDCs were not depleted at any timepoint.”
Dreyfuss, A. D., Yahalom, J., Rajeeve, S., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01607-7
“B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy produces high response rates and durable remissions in relapsed/refractory multiple myeloma (RRMM), yet most patients ultimately relapse [1, 2].”
Banerjee, R. K., Hashmi, H., Chaudhary, P. M., Atrash, S., Green, K., Ghosh, S., Bixby, T., Wiest, D. D., Perciavalle, M., Vesole, D. H., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03737-7
Self-citationMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Zhang, T., Wang, S., Li, X., Li, X., & Wu, Y. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2711554
Optimal CAR-T cell therapy options for patients with multiple myeloma
Deng, S., Xu, Y., Zou, D., Hao, M., Li, J., Qiu, L., & An, G. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004274
Duminuco, A., Palumbo, G. A., Avella, E., Cupri, A., Garibaldi, B., Limoli, M. C., Mauro, E., Patti, S., Risata, N., Romano, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176520 · Cited by 1
Fonseca, R., Brunner, M. J., Fanning, S., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2717477
Hung, Y.-C., Cho, S., Chen, Y.-Y., Hsu, Y., Huang, S., Wei, C., Tsai, C., Huang, W., & Liu, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.029
Feri, F., Hutsava, Y., Monico, R., Morena, F., & Perriello, V. M. (2026) · Biomedicines · doi:10.3390/biomedicines14091912
Straßl, I., Nikoloudis, A., Rüsing, L. Z., Melchardt, T., Leisch, M., Schulz, E., Heine, A., Neumeister, P., Steiner, N., Wolf, D., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70773
Artzenroth, J. C., Kosch, R., Al-Bazaz, M., Bartke, L., Cords, L., Güsmer, C., Harzer, M., Heinrich, F., Kamili, A., Leypoldt, L. B., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.08.044
EXABS-157-CT: Immunotherapy Trials
Kale, B. J., & Hansen, D. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00307-1
Gundroo, H. M., Nasrollahi, E., Alford, B., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70804
Self-citationMultiples Myelom: Modernes Verständnis von Heilung geht über MRD-Negativität hinaus
Weinhold, N., Raab, M., Kortüm, M., Mai, E. K., Goldschmidt, H., Einsele, H., & Rasche, L. (2026) · Deutsches Ärzteblatt · doi:10.3238/personko.2026.09.04.01
Self-citationSu, S., Yan, S., Wu, J., & Xiao, Y. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11228-z
Perron, N., Foster, K. A., Mouhieddine, T. H., Redd, R. A., Magidson, S., Perry, J. F., Sturtevant, A., Davie, C., Ricciardi, C., Blevins, F., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03092-0
Itez, G. G., & Sunguroğlu, A. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261484713 · Cited by 1
“13,14 However, as manufacturing time decreases, careful evaluation of cell quality, CRS incidence, and long-term efficacy remains critical.”
A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy
Jordana-Urriza, L., Muraro, M. G., Du, M., Lambrecht, V., Rodríguez-Madoz, J. R., Martín, I., & García‐García, A. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1860416
Treatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Martínez, S., Gómez, C., & Navarro, L. (2024) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/njbb2s214l
Ahrens, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Heins, S., Teipel, R., Mitsiades, C. S., Papadopoulos, E., Ahrens, K., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.010
Beyond CAR-T: Preventing and Treating Relapse in B-Cell Haematological Malignancies
Canichella, M., Abruzzese, E., Cefalo, M., Gianfelici, V., Mazzone, C., Trotta, G. E., Laureana, R., Cupelli, L., & Principe, M. I. D. (2026) · Cells · doi:10.3390/cells15181660
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.